Literature DB >> 26799497

Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.

Daniel L Hertz1, Megan V Caram2, Kelley M Kidwell3, Jacklyn N Thibert2, Christina Gersch2, Nicholas J Seewald3, Jeffrey Smerage2, Melvyn Rubenfire4, N Lynn Henry2, Kathleen A Cooney2,5, Monika Leja4, Jennifer J Griggs2, James M Rae2,6.   

Abstract

AIMS: Validation of associations for SNPs in RAC2, NCF4 and SLC28A3, identification of a novel association with a TOP2B SNP and screening 23 SNPs putatively relevant to anthracycline-induced cardiotoxicity. PATIENTS &
METHODS: A total of 166 breast cancer patients treated with doxorubicin underwent echocardiogram, including 19 cases with systolic dysfunction (ejection fraction <55%) and 147 controls. Four high priority SNPs were tested in the primary analysis, with appropriate statistical correction, and 23 additional SNPs were screened in an uncorrected secondary analysis.
RESULTS: Previously reported associations for RAC2, NCF4 and SLC28A3 could not be validated and a novel association with TOP2B was not discovered in this cohort (all p > 0.05), likely due to inadequate power. Two SNPs were identified in the uncorrected secondary analysis including a protective SNP in ABCB1 (3435C>T, p = 0.049) and a risk allele in CBR3 (V244M, p = 0.012).
CONCLUSION: The associations reported in prior publications and those discovered in this secondary analysis require further replication in independent cohorts.

Entities:  

Keywords:  ABCB1; CBR3; NCF4; RAC2; SLC28A3; TOP2B; anthracycline; cardiotoxicity; doxorubicin; pharmacogenetic; systolic dysfunction

Mesh:

Substances:

Year:  2016        PMID: 26799497      PMCID: PMC5558515          DOI: 10.2217/pgs.15.162

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  33 in total

1.  Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

Authors:  Javier G Blanco; Can-Lan Sun; Wendy Landier; Lu Chen; Diego Esparza-Duran; Wendy Leisenring; Allison Mays; Debra L Friedman; Jill P Ginsberg; Melissa M Hudson; Joseph P Neglia; Kevin C Oeffinger; A Kim Ritchey; Doojduen Villaluna; Mary V Relling; Smita Bhatia
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

2.  Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.

Authors:  Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Victor Cohen; Sucheta Gosavi; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie
Journal:  Am J Cardiol       Date:  2011-03-02       Impact factor: 2.778

3.  Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.

Authors:  Henk Visscher; Colin J D Ross; S Rod Rassekh; Amina Barhdadi; Marie-Pierre Dubé; Hesham Al-Saloos; George S Sandor; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Andrew M K Brown; Paul C Rogers; Michael S Phillips; Michael J Rieder; Bruce C Carleton; Michael R Hayden
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

4.  Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells.

Authors:  Gisela Kersting; Mladen V Tzvetkov; Klaus Huse; Bettina Kulle; Verena Hafner; Jürgen Brockmöller; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-07       Impact factor: 3.000

5.  Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Authors:  Daniela Cardinale; Alessandro Colombo; Maria T Sandri; Giuseppina Lamantia; Nicola Colombo; Maurizio Civelli; Giovanni Martinelli; Fabrizio Veglia; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

6.  Tissue distribution of the multidrug resistance protein.

Authors:  M J Flens; G J Zaman; P van der Valk; M A Izquierdo; A B Schroeijers; G L Scheffer; P van der Groep; M de Haas; C J Meijer; R J Scheper
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

7.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors:  Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal:  Nat Med       Date:  2012-10-28       Impact factor: 53.440

8.  Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.

Authors:  Henk Visscher; S Rod Rassekh; George S Sandor; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Paul C Rogers; Michael J Rieder; Bruce C Carleton; Michael R Hayden; Colin J Ross
Journal:  Pharmacogenomics       Date:  2015-07-31       Impact factor: 2.533

9.  Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.

Authors:  Pei Jye Voon; Hui Ling Yap; Cho-Yee-Thu Ma; Fan Lu; Andrea L A Wong; Nur Sabrina Sapari; Richie Soong; Thomas I P Soh; Boon-Cher Goh; How-Sung Lee; Soo-Chin Lee
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

10.  Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.

Authors:  Lu Fan; Boon-Cher Goh; Chiung-Ing Wong; Norita Sukri; Siew-Eng Lim; Sing-Huang Tan; Jia-Yi Guo; Robert Lim; Hui-Ling Yap; Yok-Moi Khoo; Philip Iau; How-Sung Lee; Soo-Chin Lee
Journal:  Pharmacogenet Genomics       Date:  2008-07       Impact factor: 2.089

View more
  23 in total

1.  Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology.

Authors:  Marelize Swart; Wesley M Stansberry; Victoria M Pratt; Elizabeth B Medeiros; Patrick J Kiel; Fei Shen; Bryan P Schneider; Todd C Skaar
Journal:  J Mol Diagn       Date:  2019-02-20       Impact factor: 5.568

Review 2.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

3.  Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy.

Authors:  J E Megías-Vericat; P Montesinos; M J Herrero; F Moscardó; V Bosó; L Rojas; D Martínez-Cuadrón; R Rodríguez-Veiga; L Sendra; J Cervera; J L Poveda; M Á Sanz; S F Aliño
Journal:  Pharmacogenomics J       Date:  2017-05-09       Impact factor: 3.550

Review 4.  Cardiotoxicity of Contemporary Breast Cancer Treatments.

Authors:  Katherine Lee Chuy; Anthony F Yu
Journal:  Curr Treat Options Oncol       Date:  2019-05-09

5.  Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial.

Authors:  Daniel J Serie; Julia E Crook; Brian M Necela; Travis J Dockter; Xue Wang; Yan W Asmann; DeLisa Fairweather; Katelyn A Bruno; Gerardo Colon-Otero; Edith A Perez; E Aubrey Thompson; Nadine Norton
Journal:  Pharmacogenet Genomics       Date:  2017-10       Impact factor: 2.089

6.  Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer-A Children's Oncology Group ALTE03N1 report.

Authors:  Purnima Singh; Xuexia Wang; Lindsey Hageman; Yanjun Chen; Tarek Magdy; Wendy Landier; Jill P Ginsberg; Joseph P Neglia; Charles A Sklar; Sharon M Castellino; Zoann E Dreyer; Melissa M Hudson; Leslie L Robison; Javier G Blanco; Mary V Relling; Paul Burridge; Smita Bhatia
Journal:  Cancer       Date:  2020-05-15       Impact factor: 6.860

Review 7.  Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.

Authors:  Vivian Y Chang; Jessica J Wang
Journal:  Curr Oncol Rep       Date:  2018-04-30       Impact factor: 5.075

Review 8.  Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.

Authors:  Tarek Magdy; Paul W Burridge
Journal:  Pharmacogenomics       Date:  2021-01-15       Impact factor: 2.533

9.  CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin.

Authors:  Jennifer K Lang; Badri Karthikeyan; Adolfo Quiñones-Lombraña; Rachael Hageman Blair; Amy P Early; Ellis G Levine; Umesh C Sharma; Javier G Blanco; Tracey O'Connor
Journal:  Cardiooncology       Date:  2021-05-11

10.  Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.

Authors:  Xinyu Yang; Guoping Li; Manke Guan; Aneesh Bapat; Qianqian Dai; Changming Zhong; Tao Yang; Changyong Luo; Na An; Wenjing Liu; Fan Yang; Haie Pan; Pengqian Wang; Yonghong Gao; Ye Gong; Saumya Das; Hongcai Shang; Yanwei Xing
Journal:  Front Cardiovasc Med       Date:  2021-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.